Trevor Johnson is Principal Scientist in the Translational Science team at Certara (formerly Simcyp). His research areas focus on pediatric oral drug absorption and biologics, ontogeny of enzymes and transporters, and special populations, particularly hepatic and renal impairment. After previously working as a pediatric hospital pharmacist, he obtained his Ph.D. in Pediatric Clinical Pharmacology, followed by a postdoc in population pharmacokinetics at the University of Sheffield. He has over 95 publications, 3766 citations, and an h-index of 33 (Scopus, 27 September 2023).
Manuela Grimstein, Ph.D., is an acting
team leader for the Physiologically based Pharmacokinetic (PBPK) team in the
Division of Pharmacometrics in the Office of Clinical Pharmacology, the FDA. Prior to that,
she worked as a clinical pharmacology reviewer in the Division of Inflammation
and Immune Pharmacology. She received her Ph.D. degree from the Department of
Pharmaceutics, the College of Pharmacy, University of Florida, in 2011, and her
Bachelor of Pharmacy and Master's of Science degree in Pharmaceutical Sciences
from the Federal University of Minas Gerais, Brazil, in 2006. Her research
interests include the application of physiologically based pharmacokinetic
models to evaluate the effect of patient intrinsic and extrinsic factors on
drug exposure, specifically, the effect of age, renal function, comedications,
genetic polymorphism, and pregnancy on drug exposure. Her work has been
published in highly cited peer-reviewed journals.
Tamorah Lewis is a physician scientist and the Division Head for Clinical Pharmacology and Toxicology at SickKids. In this role, her goal is to advance the hospital-wide vision for Precision Child Health and collaborate with multiple clinical Divisions to research and implement precision therapeutics. She will provide clinical care in the Level IV NICU at SickKids. Prior to this new role, she was at Children's Mercy Kansas City in the Divisions of Neonatology and Pediatric Clinical Pharmacology for seven years. She worked as an attending in the Level IV NICU and led translational/clinical research in neonatal pharmacology.
